The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125210841 12521084 1 I 20140528 20160701 20160701 EXP NO-PFIZER INC-2379495 PFIZER 26.00 YR M Y 0.00000 20160701 OT NO NO

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125210841 12521084 1 PS PREDNISOLONE. PREDNISOLONE 1 40 MG/M2, UNK U 0 40 MG/M**2
125210841 12521084 2 SS PREDNISONE. PREDNISONE 1 Intrathecal 10 MG, UNK U UNK 0 10 MG
125210841 12521084 3 SS PREDNISONE. PREDNISONE 1 Oral 40 MG/M2, UNK U UNK 0 40 MG/M**2
125210841 12521084 4 C VINCRISTINE SULFATE. VINCRISTINE SULFATE 1 Intravenous (not otherwise specified) 1.5 MG/M2,MAX 2.0 MG UNK 0 1.5 MG/M**2
125210841 12521084 5 C VINCRISTINE SULFATE. VINCRISTINE SULFATE 1 Intravenous (not otherwise specified) 0.5MC/G/KG/HR UNK 0
125210841 12521084 6 C CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 Intravenous (not otherwise specified) 750 MG/M2, UNK UNK 0 750 MG/M**2
125210841 12521084 7 C CYTARABINE. CYTARABINE 1 Intrathecal 40 MG, UNK UNK 0 40 MG
125210841 12521084 8 C CYTARABINE. CYTARABINE 1 Intravenous (not otherwise specified) 200 MG/M2, UNK UNK 0 200 MG/M**2
125210841 12521084 9 C DAUNORUBICIN DAUNORUBICIN 1 Intravenous (not otherwise specified) 50 MG/M2, UNK UNK 0 50 MG/M**2
125210841 12521084 10 C DOXORUBICIN DOXORUBICIN 1 Intravenous (not otherwise specified) 30 MG/M2, UNK UNK 0 30 MG/M**2
125210841 12521084 11 C G-CSF GRANULOCYTE COLONY-STIMULATING FACTOR NOS 1 10 MCG/KG/DAY UNK 0
125210841 12521084 12 C L-ASPARAGINASE ASPARAGINASE 1 Intravenous (not otherwise specified) 10000 IU, UNK UNK 0 10000 IU
125210841 12521084 13 C MERCAPTOPURINE. MERCAPTOPURINE 1 Oral 35 MG/M2, UNK UNK 0 35 MG/M**2
125210841 12521084 14 C METHOTREXATE. METHOTREXATE 1 Intrathecal 15 MG, UNK UNK 0 15 MG
125210841 12521084 15 C METHOTREXATE. METHOTREXATE 1 Intravenous (not otherwise specified) 1500 MG/M2, UNK UNK 0 1500 MG/M**2
125210841 12521084 16 C THIOGUANINE THIOGUANINE 1 Intravenous (not otherwise specified) 150 MG/M2, UNK UNK 0 150 MG/M**2

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125210841 12521084 1 Precursor T-lymphoblastic lymphoma/leukaemia
125210841 12521084 2 Precursor B-lymphoblastic lymphoma
125210841 12521084 4 Precursor B-lymphoblastic lymphoma
125210841 12521084 6 Precursor B-lymphoblastic lymphoma
125210841 12521084 7 Precursor B-lymphoblastic lymphoma
125210841 12521084 9 Precursor B-lymphoblastic lymphoma
125210841 12521084 10 Precursor B-lymphoblastic lymphoma
125210841 12521084 11 Peripheral blood stem cell apheresis
125210841 12521084 12 Precursor B-lymphoblastic lymphoma
125210841 12521084 13 Precursor B-lymphoblastic lymphoma
125210841 12521084 14 Precursor B-lymphoblastic lymphoma
125210841 12521084 16 Precursor B-lymphoblastic lymphoma

Outcome of event

Event ID CASEID OUTC COD
125210841 12521084 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125210841 12521084 Osteonecrosis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125210841 12521084 5 20080624 20080624 0